|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
|
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel.
|
28193529 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All four patients with distant metastasis had BRAF(V600E) mutation.
|
22767446 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All four patients with distant metastasis had BRAF(V600E) mutation.
|
22767446 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All patients with lateral cervical node metastasis (n=9), and all but one tumor with extrathyroidal extension (n=17/18) showed BRAF(V600E) mutation.
|
22918165 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All patients with lateral cervical node metastasis (n=9), and all but one tumor with extrathyroidal extension (n=17/18) showed BRAF(V600E) mutation.
|
22918165 |
2013 |
|
rs4986790
|
|
|
0.040 |
GeneticVariation |
BEFREE |
All polymorphisms detected were also significantly associated with the metastatic disease (p<0.001) leading to shorter overall survival (p<0.001); whereas, TLR4 Asp299Gly and Thr399Ile polymorphisms were significantly associated with KRAS mutations.
|
29883450 |
2018 |
|
rs4986791
|
|
|
0.020 |
GeneticVariation |
BEFREE |
All polymorphisms detected were also significantly associated with the metastatic disease (p<0.001) leading to shorter overall survival (p<0.001); whereas, TLR4 Asp299Gly and Thr399Ile polymorphisms were significantly associated with KRAS mutations.
|
29883450 |
2018 |
|
rs1053129
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Also patients homozygous for the G allele of rs1053129 in the dihydrofolate reductase (DHFR) gene were more likely to have a metastasis (45%, P= 0.005), and the methylenetetetrahydrofolate reductase (MTHFR) 677C allele was associated with higher degree of liver toxicity (88%, P=0.007).
|
25778468 |
2015 |
|
rs121912664
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Among the 19 patients with the Arg337His mutation, only one boy and three adults showed fatal evolution or recurrent metastases.
|
11600572 |
2001 |
|
rs4986790
|
|
|
0.040 |
GeneticVariation |
BEFREE |
An improved overall survival (Hazard ratio HR 0.53, 95% CI 0.32-0.88) and survival following metastasis (HR 0.55, 95% CI 0.34-0.91) were observed in carriers of the variant allele (D299G) of TLR4-rs4986790.
|
21931695 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analysis of the metastatic tumor demonstrated clonal expansion of a BRAF V600E subpopulation.
|
29744614 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analysis of the metastatic tumor demonstrated clonal expansion of a BRAF V600E subpopulation.
|
29744614 |
2018 |
|
rs1057519816
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Another patient with the S310F mutation had an apocrine carcinoma with seven lymph nodes positive for metastasis, classified as HER2 3+ by the HercepTest, but which was FISH-negative, as well as ER-negative and PgR-negative.
|
26642960 |
2016 |
|
rs121913227
|
|
|
0.080 |
GeneticVariation |
BEFREE |
As to the B-raf protein sequence, the acidic amino acid transitions V599E and V599K were predicted in 19/60 (32%) and 6/60 (10%) cases, respectively, but were not associated with enhanced risk for subsequent metastasis in patients' follow up.
|
15935100 |
2005 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations between BRAF V600E and TERT promoter mutations and clinicopathological features, Tumor-Node-Metastasis stage, initial risk, response to therapy, follow-up, and final disease outcome were assessed according to American Thyroid Association 2015 criteria and the American Joint Committee on Cancer/Tumor-Node-Metastasis (8th edition) staging system.Median follow-up was 120 months.
|
31305897 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations between BRAF V600E and TERT promoter mutations and clinicopathological features, Tumor-Node-Metastasis stage, initial risk, response to therapy, follow-up, and final disease outcome were assessed according to American Thyroid Association 2015 criteria and the American Joint Committee on Cancer/Tumor-Node-Metastasis (8th edition) staging system.Median follow-up was 120 months.
|
31305897 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
rs12190287
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Besides, rs12190287 CG and GG genotypes are associated with Enneking stage and potential in forming metastasis of osteosarcoma.
|
28663539 |
2017 |
|
rs115785973
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Besides, SNP rs115785973 in SOCS3 was identified as a risk factor in the occurrence of GC highly associated with poor differentiation grade, larger tumor size and metastasis.
|
27160093 |
2016 |
|
rs754854286
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bioluminescent imaging showed that intracardiac injection of MCF7/TG2-C277S cells in mice promoted bone tumors, especially in the knee and jaw, but MCF7/TG2-C277S cells ectopically expressing miR-205 did not metastasize.
|
30949413 |
2019 |
|
rs3804329
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both rs1322178 and rs3804329 can predict early distant metastasis of patients.
|
29207660 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) mutation.
|
22435913 |
2012 |